JPRN-UMIN000038644招募中未知
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer. - PATROL-II
Hoshi University Division of Applied Pharmaceutical0 个研究点目标入组 89 人开始时间: 2019年11月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 89
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who has history of hypersensitivity or allergy for study drugs or similar compounds. 2) Patients taking systemic corticosteroid (oral and intravenous) except for inhaled or topical corticosteroid preparation 3) Patients having a clear vomiting symptom such as brain metastasis or gastrointestinal obstruction to the passage of foods 4) Patients with symptomatic ascites or pleural effusions requiring therapeutic puncture 5) Patients with obstruction of gastrointestinal tract, for example gastric outlet or ileus etc. 6) Patients who have convulsive disorders requiring anticonvulsants therapy 7) Patients receieving adrenaline or pimozide 8) Patients who start taking opioids within 48 h prior to registration 9) Patients who received radiation therapy to abdomen or pelvis within 6 days prior to registration or will receive radiation therapy until 6 days after cisplatin administration 10) Patients regularly taking antiemetics other than study drugs 11) Pregnant, breastfeeding or expecting women or who do not wish to use contraception 12) Patients with diabetes mellitus receiving treatment of antidiabetic agents or having HbA1c (NGSP) 6.5 or more, or HbA1c (NGSP) in less than 28 days before registration is the patient with (in the case of JDS more than 6.1%) 6.5% or more. 13) Patients with smoking habit 14) The patients who have difficulty in operation such as the input, and the like of EDC. 15) Patients who are judged to be inappropriate for the study by the investigator
研究者
相似试验
进行中（未招募）
1 期
A phase II single arm, multi-centre trial of triamcinolone with a GnRH analog for castration resistant prostate cancerCastration Resistent Prostate cancerEUCTR2010-022010-32-GBBarts and The London NHS Trust41
已完成
2 期
A Multi-center Phase II Clinical trial of 3rd and more line TS-1 treatment for Advanced NSCLCSCLCJPRN-UMIN000004295Ehime University Graduate School of Medicine45
尚未招募
不适用
Vactosertib in combination with pembrolizumab in acral and mucosal melanomaKCT0007745Yonsei University Health System, Severance Hospital30
进行中（未招募）
1 期
A multi-centre 3-arm randomized phase II trial of BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancerChemo-naive hormone refractory prostate cancerEUCTR2005-005249-21-GBBoehringer Ingelheim Ltd.105
招募中
不适用
A multicentre two-arm, phase II trial assessing the safety and efficacy of first-line lazertinib and locally ablative radiotherapy in patients with synchronous oligo-metastatic EGFR-mutant non-small cell lung cancerNeoplasmsKCT0006760Yonsei University Health System, Severance Hospital68